Harvard University

Harvard University

Cambridge, MA 02138

United States

Widening the therapeutic index for pediatric medulloblastoma by targeting BET proteins

Treatment of human cancers with chemotherapy or radiation with curative intent has led to the successful eradication of tumors in millions of patients, yet the cell death induced in healthy tissues drastically limits their use. This is especially true for pediatric cancer patients, who frequently experience higher cure rates than adults but, unfortunately, also higher rates of treatment-induced toxicities and long-term adverse health effects.

Targeting the Metabolic Drivers of Chemo Resistance in Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML)

Background

Acute myeloid leukemia (AML) is one of the most challenging childhood cancers to treat. Induction chemotherapy remains the standard of care, but the incidence of refractory and relapsed AML is high. It remains unclear how certain AML cells manage to survive the extreme stress of chemotherapy. The search for specific genetic mutations that lead to therapy resistance has thus far not been successful. While mutations may certainly play a role, cells have other systems to protect them from stress, such as shifting metabolic programs.

Validation of CDK12 Inhibition in Osteosarcoma

Osteosarcoma

Background

Assessing Combinatory Effect of PARP Inhibitor with DNA Damaging Agent on Rhabdomyosarcoma at Single Cell Resolution

Rhabdomyosarcoma

Alex's Lemonade Stand Foundation for Childhood Cancer